bluebird bio Announces Transition Of Chief Scientific Officer
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, today announced that Mitchell H. Finer, Ph.D., chief scientific officer (CSO), has decided to transition from his current role with bluebird bio over the next six months.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.